Back to Search Start Over

Effects of Metallic and Carbon-Based Nanomaterials on Human Pancreatic Cancer Cell Lines AsPC-1 and BxPC-3.

Authors :
Wójcik B
Sawosz E
Szczepaniak J
Strojny B
Sosnowska M
Daniluk K
Zielińska-Górska M
Bałaban J
Chwalibog A
Wierzbicki M
Source :
International journal of molecular sciences [Int J Mol Sci] 2021 Nov 09; Vol. 22 (22). Date of Electronic Publication: 2021 Nov 09.
Publication Year :
2021

Abstract

Pancreatic cancer, due to its asymptomatic development and drug-resistance, is difficult to cure. As many metallic and carbon-based nanomaterials have shown anticancer properties, we decided to investigate their potential use as anticancer agents against human pancreatic adenocarcinoma. The objective of the study was to evaluate the toxic properties of the following nanomaterials: silver (Ag), gold (Au), platinum (Pt), graphene oxide (GO), diamond (ND), and fullerenol (C <subscript>60</subscript> (OH) <subscript>40</subscript> ) against the cell lines BxPC-3, AsPC-1, HFFF-2, and HS-5. The potential cytotoxic properties were evaluated by the assessment of the cell morphology, cell viability, and cell membrane damage. The cancer cell responses to GO and ND were analysed by determination of changes in the levels of 40 different pro-inflammatory proteins. Our studies revealed that the highest cytotoxicity was obtained after the ND treatment. Moreover, BxPC-3 cells were more sensitive to ND than AsPC-1 cells due to the ND-induced ROS production. Furthermore, in both of the cancer cell lines, ND caused an increased level of IL-8 and a decreased level of TIMP-2, whereas GO caused only decreased levels of TIMP-2 and ICAM-1 proteins. This work provides important data on the toxicity of various nanoparticles against pancreatic adenocarcinoma cell lines.

Details

Language :
English
ISSN :
1422-0067
Volume :
22
Issue :
22
Database :
MEDLINE
Journal :
International journal of molecular sciences
Publication Type :
Academic Journal
Accession number :
34829982
Full Text :
https://doi.org/10.3390/ijms222212100